"while maintaining a strong cash position of $32.8 million as at 31 March 2025."
That's a strong cash balance maintained for the end of the quarter. Costs are low and the Australian pharmacy sales rollout is to begin this quarter.
" Further distribution preparations made, having completed implementation and planning with Symbionfor the Q2 CY25 rollout, which will establish nationwide pharmacy distribution capabilities over the coming quarters."
That should see sales pick up off the current low base and the stronger growth in sales will be early next year with the US compounding market possibly seeing the company go cash flow positive ahead of the FDA approval and larger scale US sales - hopefully by the end of next year or early the following year.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)